Status:

UNKNOWN

Comparison Between Pylorus-resecting and Preserving Pancreaticoduodenectomy on Delayed Gastric Emptying and Nutrition

Lead Sponsor:

Asan Medical Center

Conditions:

Pancreaticoduodenectomy

Delayed Gastric Emptying

Eligibility:

All Genders

18-79 years

Phase:

NA

Brief Summary

Pylorus preserving pancreaticoduodenectomy has been standard procedure for periampullary benign and malignant disease. Delayed gastric emptying is one of most common complications after the procedure....

Detailed Description

Pylorus preserving pancreaticoduodenectomy has been standard procedure for periampullary benign and malignant disease. Delayed gastric emptying is one of most common complications after the procedure....

Eligibility Criteria

Inclusion

  • Age: 18 to 79 years
  • Performance: Eastern Cooperative Oncology Group (ECOG) 0-2
  • The preoperative examination showed that the lesion could invade to major artery.
  • No distant metastasis
  • Bone marrow function: white blood cell (WBC) at least 3,000 / mm3, Platelet count at least 100,000 / mm3
  • Liver function : aspartate transaminase (AST)/alanine transaminase(ALT) less than 3 times upper limit of normal
  • Kidney function: Creatinine no greater than 1.5 times upper limit of normal.
  • Patients who consented to and signed the consent

Exclusion

  • Patients diagnosed with duodenal cancer
  • Those with active or uncontrolled infections
  • Those with severe psychiatric / neurological disorders
  • Alcohol or other drug addicts
  • Patients who underwent previous major abdominal surgery (ex. gastrectomy, colectomy)
  • Patients included in other clinical studies that may affect this study
  • Patients who cannot follow the directions of the researcher
  • Those with uncontrolled heart disease
  • Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (ex. cirrhosis, chronic kidney failure, heart failure, etc.)
  • Pelvic tumor, benign tumor, malignant tumor in other organs
  • Patients who received prior chemotherapy
  • In addition to the planned pancreaticoduodenectomy, patients who require resection of other major abdominal organs, such as gastrectomy, colectomy

Key Trial Info

Start Date :

May 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 28 2025

Estimated Enrollment :

394 Patients enrolled

Trial Details

Trial ID

NCT05314244

Start Date

May 1 2022

End Date

April 28 2025

Last Update

April 6 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.